ClinicalTrials.gg
Status unknownNCT05116410Updated Jul 19, 2022

A Study of HS-20094 in Healthy Participants

A Phase 1 interventional study of HS-20094 and Placebo in Type 2 Diabetes, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-19.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Oct 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Diabetes Mellitus, Type 2 by Hansoh Pharmaceutical Group Company Limited — 2 open to participants now, 2 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Hansoh Pharmaceutical Group Company Limited.

Planned enrollment
6th of 12
68 · median 61
Started
2021
the only one that year
Phase 1
6 of 12
none open now
Registered
8th of 12
by date

Among the 12 studies in Diabetes Mellitus, Type 2 by Hansoh Pharmaceutical Group Company Limited, this one is the 6th largest by planned enrollment, is the only one that started in 2021, is one of 6 in phase 1, and was the 8th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 12 studies in Diabetes Mellitus, Type 2 by Hansoh Pharmaceutical Group Company Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Diabetes Mellitus, Type 2 by Hansoh Pharmaceutical Group Company Limited, or all of them as a file.
02

Study summary

This study includes two parts (Single Ascending Dose, SAD; Multiple-Ascending Dose, MAD) and enrolls healthy participants. Participants in SAD accept single subcutaneous (SC) injection of HS-20094 and participants in MAD accept SC injection of HS-20094 once weekly for 4 weeks. The main purpose of this study is to determine 1) The safety of HS-20094; 2) How much HS-20094 gets into the bloodstream and how long it takes the body to get rid of it.3) How HS-20094 affects the levels of blood sugar, insulin and weight.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Screening weight of male ≥50 kg, female≥45 kg and 19≤≤28
  2. Subjects agree to use an effective method of and avoid sperm or egg donation for the duration of the study and for 6 months following the last dose of product
  3. Agree to avoid alcohol, foods and beverages containing xanthine or caffeine (including chocolate, tea, coffee, cola, etc.) from 48 hours prior to administration to last visit, and to avoid strenuous exercise

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women
  2. Subjects have a medical history of cardiovascular, respiratory, liver, kidney, digestive tract, mental, neurological, hematology or metabolic abnormalities (e.g., repeated hypoglycemia for unknown reasons) and are judged not suitable for this study by the investigator.
  3. Subjects with abnormal screening vital signs, physical examination, laboratory examination or 12 lead results with clinical significance
  4. Have a history of drug allergy, or known allergies to HS-20094, glucagon-like peptide (GLP)-1 analogs, or glucose-dependent insulinotropic polypeptide (GIP) receptor agonism
  5. Received systemic therapy, immunomodulator therapy or chemotherapy in the 3 months prior to screening, or are likely to receive these treatments during the study period
  6. Have a history of digestive disease (e.g., gastroesophageal reflux disease, gallbladder disease, or chronic enteritis) that may affect gastrointestinal adverse events assessment or any other gastrointestinal disease (e.g., gastric bypass surgery, pyloric stenosis, etc.) that may affect gastric emptying
  7. Have a diet, weight loss treatment or significant lifestyle changes prior to 30 days of administration
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    HS-20094 (Single dose)

    Escalating doses of HS-20094 administered subcutaneously (SC) once in healthy participants.

    Drug: HS-20094

  • Experimental
    HS-20094 (Multiple doses)

    Escalating doses of HS-20094 administered SC once weekly for four weeks in healthy participants.

    Drug: HS-20094

  • Placebo comparator
    Placebo (Single dose)

    Placebo administered SC once in healthy participants.

    Drug: Placebo

  • Placebo comparator
    Placebo (Multiple doses)

    Placebo administered SC once weekly for four weeks in healthy participants.

    Drug: Placebo

Interventions

  • Administrated SC

    Also known as: HS-20094 injection

  • DrugPlacebo

    Administrated SC

    Also known as: Placebo injection

06

What researchers measure

Primary outcomes

  1. Incidence of adverse event (AE), serious adverse event (SAE), AE leading to study discontinuation, AE severity and relation with study drug

    A summary of AEs and SAEs, AE leading to study discontinuation, AE severity and relation with study drug will be reported in the reported adverse events module

    Time frame: Time of Inform Consent Form to Day 29 (SAD) or Day 50 (MAD)

Secondary outcomes

  1. Pharmacokinetics (PK): Cmax of HS-20094

    PK: Cmax of HS-20094

    Time frame: Baseline to Day 22 (SAD) or Day 43 (MAD)

  2. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of HS-20094

    PK: AUC of HS-20094

    Time frame: Baseline to Day 22 (SAD) or Day 43 (MAD)

  3. Pharmacokinetics (PK): Tmax of HS-20094

    PK: Tmax of HS-20094

    Time frame: Baseline to Day 22 (SAD) or Day 43 (MAD)

  4. Pharmacodynamics (PD): AUC of glucose

    PD: AUC of glucose

    Time frame: Day 22 (MAD)

  5. Pharmacodynamics (PD): AUC of insulin

    PD: AUC of insulin

    Time frame: Day 22 (MAD)

  6. Weight change

    Time frame: baseline to Day 29 (SAD) or Day 50 (MAD)

07

Study locations

1 of 1 sites recruiting
  • Beijing University First Hospital
    Beijing, Beijing 110000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Oct 2022, 11 months after the start.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's planned 11 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2021
First posted
Nov 11, 2021
StartActual
Nov 1, 2021
Primary completionEst.
Oct 31, 2022
CompletionEst.
Dec 31, 2022
Last update
Jul 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05116410
Responsible party
Sponsor
First posted
Nov 11, 2021
Start date
Nov 1, 2021
Primary completion
Oct 31, 2022 (estimated)
Completion
Dec 31, 2022 (estimated)
Last update
Jul 19, 2022

Study contacts

Yimin Cui, PhD
Contact
cuiymzy@126.com
66110802 ext. 010
Yimin Cui
principal investigator · Beijing University First Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HS-20094

Start the discussion